Diamyd Medical has been given notice that the USPTO has allowed a patent application and is expected to proceed to grant a patent protecting the use of retogatein (GAD65) to treat individuals with type 1 diabetes carrying the HLA DR3-DQ8 genetic marker. The patent is valid until 2038 and is important to the company's global IP portfolio in precision medicine for type 1 diabetes.
Diamyd Medical currently holds granted precision medicine patents, or has been given notice of allowance, for treating and preventing type 1 diabetes in key global markets:
Together, these two genetic markers - HLA DR3-DQ2 and DR4-DQ8 - are present in up to 90% of individuals with type 1 diabetes, underscoring their broad clinical relevance.
About Diamyd Medical
Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company's investigational drug candidate retogatein, based on recombinant GAD65, was evaluated in the Phase 3 DIAGNODE-3 trial in recent-onset type 1 diabetes. The Company has established a facility for manufacturing of biological products in Umeå, Sweden.
Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.